Related Experiment Video
Updated: Sep 9, 2025

Cell Type-specific Gene Expression Profiling in the Mouse Liver
Published on: September 17, 2019
Febuxostat-induced hepatocellular injury
Joanne Lin1,2, David Braxton3, Tse-Ling Fong4
1Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA joanne.lin@ucsf.edu.
Abstract:
Febuxostat is a non-purine xanthine oxidase inhibitor primarily used to treat gout and hyperuricaemia. Although it has a better safety profile compared to allopurinol, febuxostat has been associated with rare cases of drug-induced liver injury. We present a case of a man in his late 50s who developed liver injury after switching from allopurinol to febuxostat for gout management. The patient experienced fatigue, nausea, jaundice and had notably elevated aminotransferase activities. A liver biopsy revealed moderate acute hepatocellular injury. After discontinuing febuxostat, the liver tests did not improve for 1 month until treatment with prednisone. This case adds to the existing literature on febuxostat-induced liver injury and highlights the variability in clinical and histological manifestations. It also emphasises the importance of monitoring liver tests in patients taking febuxostat.
Related Concept Videos
Phase II Reactions: Glucuronidation
Hepatic Drug Excretion: Influencing Factors
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drug Metabolism: Phase II Reactions
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

